ESG Viewpoint: Diversity in clinical trials  

ESG Viewpoint: Diversity in clinical trials  

Despite a clear scientific and commercial imperative, a significant gap between patient and trial populations persists.  We explain why diversity in clinical trials matters to investors and explore our engagement with companies.   

Diversity in clinical trials is, first and foremost, a scientific imperative, but also increasingly a regulatory and commercial requirement. A trial population that represents the diversity of the target patient population is important for the full evaluation of safety and efficacy and building patient trust. However, for various operational and historical reasons, it is rarely straightforward to achieve. As investors, we are interested in assessing strategic thinking, action and progress on this topic across the sector, and encouraging improvements. Considerable groundwork is needed to enable greater trial diversity, and a failure to take timely steps risks delays and additional cost to drug development, which may impact commercial success.

Why trials matter

Clinical trials are designed to evaluate the effect of interventions (such as drugs, devices, surgeries and diets) on health-related biomedical or behavioural outcomes.1 To account for different genetic, (patho)physiological traits, as well as social determinants of health, it is important to include people that account for diverse traits and circumstances in clinical trials and reflect the epidemiology of the disease. As an example, women of colour are 41% more likely to die of breast cancer than white women, and they have a 39% higher recurrence rate.2 However, for four new breast cancer treatments that were approved by the Food and Drug Administration (FDA) in 2020, black clinical trial participants only made up 2-9% of clinical trial participants.3 Of the 53 novel drugs approved in 2020 by the FDA, 75% of trial participants were white, whereas 40% of the US population is comprised of minority racial and ethnic groups.4&5

Gaining a full understanding of the safety and efficacy of novel therapies across all demographics can only be achieved when clinical trial enrolment is representative.6 When companies are able to better identify safety issues for certain populations prior to market entry, this can limit financial and legal risks resulting from product recalls and patient litigation.7 Upcoming regulatory requirements will push the industry to include diversity planning in their trial protocol or justify why this is not necessary. Being unprepared for this might result in novel drugs and therapies not being approved by the FDA, which poses a very material risk to drug manufacturers and Contract Research Organisations (CROs).

In addition, we consider improving diversity in clinical trials as an opportunity for the industry to enhance trust-building with current and future patients. As trust in the pharmaceutical sector is a persistent issue that also affects drug and vaccine uptake, trust-building has the potential to have a much wider effect on pharmaceutical companies. Studies find that higher levels of trust among disadvantaged communities can be expected to contribute to better health outcomes for their members, and can drive, in turn, a virtuous cycle – from higher-quality data to more expansive problem solving to better-targeted approaches, and to greater collaboration throughout the healthcare ecosystem.8 This will ultimately be beneficial for the industry itself as higher trust will most likely also positively impact areas other than clinical trials – for instance, drug and vaccine uptake.

Interested in learning more?

We discuss why this is material for investors and what different barriers exist to diversifying clinical trials. We also explain how we engage investee companies on this topic and which good practices we have identified from this.  Download the full ESG Viewpoint to learn more.

4 January 2024
Ellen Brauers
Associate, Responsible Investment team
Share article
Share on linkedin
Share on email
Key topics
Related topics
Listen on stitcher badge
Share on twitter
Share on linkedin
Share on email
Key topics
Related topics


ESG Viewpoint: Diversity in clinical trials  

Related Insights

21 June 2024

James Coke

Fund Manager & Co-head of Institutional UK Real Estate

Emma Gullifer

Assistant Fund Manager

Green to gold: realising opportunities from the carbon transition

We explore the interventions required to monetise green energy, and how investors might benefit from the carbon transition.
Read time - 2 min
20 June 2024

Gary Smith

Client Portfolio Manager, Fixed Income

What do geopolitical risks mean for central bank FX reserves managers?

Two major industry surveys show that adjusting for geopolitical challenges will impact the way foreign exchange reserves are managed
Read time - 8 min
19 June 2024

Sally Springer

Senior Thematic Research Analyst, Global Research

Human capital – supply: the impact of demographic transition on investments

Working populations are in decline, with the demographic dividend that has supported economic growth in many developed markets under threat. This will have a direct impact on the firms in which we invest.
Read time - 8 min

Important Information

For use by professional clients and/or equivalent investor types in your jurisdiction (not to be used with or passed on to retail clients). For marketing purposes.

This document is intended for informational purposes only and should not be considered representative of any particular investment. This should not be considered an offer or solicitation to buy or sell any securities or other financial instruments, or to provide investment advice or services. Investing involves risk including the risk of loss of principal. Your capital is at risk.  Market risk may affect a single issuer, sector of the economy, industry or the market as a whole. The value of investments is not guaranteed, and therefore an investor may not get back the amount invested. International investing involves certain risks and volatility due to potential political, economic or currency fluctuations and different financial and accounting standards. The securities included herein are for illustrative purposes only, subject to change and should not be construed as a recommendation to buy or sell. Securities discussed may or may not prove profitable. The views expressed are as of the date given, may change as market or other conditions change and may differ from views expressed by other Columbia Threadneedle Investments (Columbia Threadneedle) associates or affiliates. Actual investments or investment decisions made by Columbia Threadneedle and its affiliates, whether for its own account or on behalf of clients, may not necessarily reflect the views expressed. This information is not intended to provide investment advice and does not take into consideration individual investor circumstances. Investment decisions should always be made based on an investor’s specific financial needs, objectives, goals, time horizon and risk tolerance. Asset classes described may not be suitable for all investors. Past performance does not guarantee future results, and no forecast should be considered a guarantee either. Information and opinions provided by third parties have been obtained from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. This document and its contents have not been reviewed by any regulatory authority.

In Australia:
Issued by Threadneedle Investments Singapore (Pte.) Limited [“TIS”], ARBN 600 027 414.  TIS is exempt from the requirement to hold an Australian financial services licence under the Corporations Act 2001 (Cth) and relies on Class Order 03/1102 in respect of the financial services it provides to wholesale clients in Australia. This document should only be distributed in Australia to “wholesale clients” as defined in Section 761G of the Corporations Act.  TIS is regulated in Singapore (Registration number: 201101559W) by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289), which differ from Australian laws.

In Singapore: Issued by Threadneedle Investments Singapore (Pte.) Limited, 3 Killiney Road, #07-07, Winsland House 1, Singapore 239519, which is regulated in Singapore by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289). Registration number: 201101559W. This advertisement has not been reviewed by the Monetary Authority of Singapore.

In Hong Kong: Issued by Threadneedle Portfolio Services Hong Kong Limited 天利投資管理香港有限公司. Unit 3004, Two Exchange Square, 8 Connaught Place, Hong Kong, which is licensed by the Securities and Futures Commission (“SFC”) to conduct Type 1 regulated activities (CE:AQA779). Registered in Hong Kong under the Companies Ordinance (Chapter 622), No. 1173058.

In Japan: Issued by Columbia Threadneedle Investments Japan Co., Ltd. Financial Instruments Business Operator, The Director-General of Kanto Local Finance Bureau (FIBO) No.3281, and a member of Japan Investment Advisers Association and Type II Financial Instruments Firms Association.

In the UK: Issued by Threadneedle Asset Management Limited, No. 573204 and/or Columbia Threadneedle Management Limited, No. 517895, both registered in England and Wales and authorised and regulated in the UK by the Financial Conduct Authority.

In the EEA: Issued by Threadneedle Management Luxembourg S.A., registered with the Registre de Commerce et des Sociétés (Luxembourg), No. B 110242 and/or Columbia Threadneedle Netherlands B.V., regulated by the Dutch Authority for the Financial Markets (AFM), registered No. 08068841.

In Switzerland: Issued by Threadneedle Portfolio Services AG, an unregulated Swiss firm or Columbia Threadneedle Management (Swiss) GmbH, acting as representative office of Columbia Threadneedle Management Limited, authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA).

In the Middle East: This document is distributed by Columbia Threadneedle Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority (DFSA).  For Distributors: This document is intended to provide distributors with information about Group products and services and is not for further distribution. For Institutional Clients: The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparties and no other Person should act upon it.


This document may be made available to you by an affiliated company which is part of the Columbia Threadneedle Investments group of companies: Columbia Threadneedle Management Limited in the UK; Columbia Threadneedle Netherlands B.V., regulated by the Dutch Authority for the Financial Markets (AFM), registered No. 08068841.

Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies.

For professional investors in EMEA APAC only

Legal and regulatory disclosures

The analysis included on this website is for professional investors in EMEA APAC. This material should not be considered as an offer, solicitation, advice or an investment recommendation. This communication is valid at the date of publication and may be subject to change without notice. Any opinions expressed are made as at the date of publication but are subject to change without notice and should not be seen as investment advice. Information obtained from external sources is believed to be reliable but its accuracy or completeness cannot be guaranteed. 

I have read and accept the terms and conditions of this site:

Thank you. You can now visit your preference centre to choose which insights you would like to receive by email.

To view and control which insights you receive from us by email, please visit your preference centre.

Woman listens to music through headphones
Play Video

CT Property Trust- Fund Manager Update

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium